Clearmind reports positive safety, tolerability in CMND-100 Phase I/II trial Part A dose escalationPUBT·17 hours agoCMND+10.96%
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial | CMND Stock NewsStockTitan·Jul 27 at 10:47 PMCMND+10.96%
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market | CMND Stock NewsStockTitan·Jul 19 at 10:55 PMCMND+10.96%
Pre-market hot trades in US stocks: Clearmind Medicine pre-market down 7.03%; Corning pre-market down 3.40%Price Alert·Jul 17 at 06:32 AMCMND+10.96%GLW+9.00%
Clearmind Medicine releases update on intranasal MEAI formulation retention studyPUBT·Jul 16 at 08:30 AMCMND+10.96%
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial | CMND Stock NewsStockTitan·Jul 12 at 11:17 PMCMND+10.96%
Clearmind Medicine posts update on CMND-100 first-in-human trial webinar insightsPUBT·Jul 13 at 07:18 AMCMND+10.96%
